Please join Pfizer at ECCMID 2024, where esteemed physicians and infectious disease specialists will share their expertise at our sponsored symposia

Optimising RSV Disease Prevention Through Vaccination Across the Lifespan

This session aims to recognise RSV as a vaccine-preventable disease, discuss burden of disease in vulnerable populations, review available evidence to support RSV prevention, and describe current RSV vaccine implementation and strategies.

Sunday, 28 April  |  8:30–10:00 CEST  |  Hall L

A Growing Problem: Tick-borne Diseases — TBE and Lyme

This symposium will raise awareness of ticks and tick-borne diseases with an emphasis on TBE and Lyme — the most important vector-borne diseases in Europe.

Sunday, 28 April  |  12:15–13:15 CEST  |  Hall L

COVID-19: Are We Meeting the Challenge?

Join our global COVID-19 experts as they use the latest COVID-19 data, insights and perspectives to discuss whether we are meeting the evolving challenge of global COVID-19 prevention and treatment.

Sunday, 28 April  |  13:30–15:30 CEST  |  Hall L

Building a Strong Defense: Addressing the Importance of Vaccination in the Evolving Pneumococcal Disease Landscape Across all Ages

This session aims to discuss the impact of pneumococcal disease in children and adults, identify prevalent serotypes causing disease, review methods for increasing vaccine uptake in adults, and highlight new options for pneumococcal vaccination in children.

Monday, 29 April  |  12:15–13:15 CEST  |  Hall N

Elevating Life Course Immunisation to Overcome the Preventable Burden of Respiratory Diseases

Against the backdrop of World Immunisation Week, join our global panel of experts to discuss:

• Impacts of the potential “tripledemic” of co-circulating vaccine-preventable respiratory viruses
• Building and sustaining robust immunisation programmes across the life course to help protect populations and support health system resilience

Tuesday, 30 April  |  8:30–10:00 CEST  |  Hall P

Influenza: Everyone Has Something to Lose

Join us as the expert faculty discuss:

• The often underestimated burden of influenza in both high-risk and
  non-high-risk populations
• The value of broad influenza vaccination, suboptimal influenza vaccine coverage, and ways to bolster vaccine confidence in the context of vaccine hesitancy and apathy

Tuesday, 30 April  |  12:15–13:15 CEST  |  Hall P

Join us for what promises to be engaging and educational events!

These sessions are organized and funded by Pfizer Inc. and may include reference to Pfizer medicines relevant to the agenda topics.
These sessions are intended for healthcare professionals and other relevant decision makers only. These sessions are not included in main event CME/CPD credit.
These educational sessions are initiated, organized, and sponsored by Pfizer Inc. www.pfizer.com.